Netherlands· NL-3c61cc580cfc

Elvanse 70 mg, harde capsules

A lisdexamfetamine product containing dexamfetamine + lisdexamfetaminedimesilaat, registered in Netherlands by Takeda Pharmaceuticals International AG Ireland Branch. The same ATC class is registered in 15 of our 19 countries.

ATC N06BA12

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about dexamfetamine + lisdexamfetaminedimesilaatAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Lisdexamfetamine is registered in 15 of 19 countries.

Countries holding a registration under ATC N06BA12 (lisdexamfetamine), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
8 of them publish a price we can compare per daily dose

Search lisdexamfetamine products by name

Lisdexamfetamine · ATC N06BA12

15 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Germany
Icelandprice
Ireland
Netherlands
Norwayprice
Polandprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lisdexamfetamine costs, country by country.

Normalised to the WHO defined daily dose (30 mg), the median price runs from $1.95 in United States to $3.28 in Switzerland — a ×1.7 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown
US figures are pharmacy acquisition cost (CMS NADAC), not retail

Open the full comparison — free account Drug prices for market access

Lisdexamfetamine · price per daily dose (30 mg)

USD · FX 28 Sept 2026

CH Switzerland$3.28
US United States$1.95 (acquisition cost)

Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: DEXAMFETAMINE + LISDEXAMFETAMINEDIMESILAAT
Manufacturer: Takeda Pharmaceuticals International AG Ireland Branch
Country: Netherlands (NL)
ATC code: N06BA12
ATC class: Lisdexamfetamine
Defined daily dose: 30 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
124497

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

217 interactions on record for lisdexamfetamine.

Graded by severity as the source publishes them — 51 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check lisdexamfetamine against other medicines How interaction checks work

Lisdexamfetamine · interactions on record

217 records

51 severe
164 moderate
2 minor

Most severe, free to view

PapaverineA03AD01severe
CisaprideA03FA02severe
DolasetronA04AA04severe
FenfluramineA08AA02severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under N06BA12

Lisdexamfetamine, as other registers publish it.

All lisdexamfetamine products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/a8c457e1-5ceb-4cd1-9d44-fcda5fbd2f14
GET /v1/drugs/a8c457e1-5ceb-4cd1-9d44-fcda5fbd2f14?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h124497_smpc.pdf",
  "strength": null,
  "atc_label": "Lisdexamfetamine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg124497",
  "excipients": [
    "AMMONIA (E 527)",
    "BRILJANTBLAUW FCF (E 133)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "ERYTHROSINE (E 127)",
    "GELATINE (E 441)",
    "IJZEROXIDE ZWART (E 172)",
    "KALIUMHYDROXIDE (E 525)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "PROPYLEENGLYCOL (E 1520)",
    "SCHELLAK (E 904)",
    "TITAANDIOXIDE (E 171)",
    "ZWARTE INKT"
  ],
  "substances": [
    "DEXAMFETAMINE",
    "LISDEXAMFETAMINEDIMESILAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h124497.pdf",
  "authorised_at": "2019/05/10",
  "procedure_number": "SE/H/1839/003",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "124497",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about lisdexamfetamine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console